Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review
Mousa, N., Abdel-Razik, A., Mousa, E., Elbadrawy, T., Hosni, K., Mousa, A., Taha, A., Elmetwalli, A. (2021). Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review. EKB Journal Management System, 5.2(2), 3-8. doi: 10.21608/mjvh.2021.158270
Nasser Mousa; Ahmed Abdel-Razik; Eman Mousa; Tasnim Elbadrawy; Khaled Hosni; Aya Mousa; Ahmed Taha; Alaa Elmetwalli. "Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review". EKB Journal Management System, 5.2, 2, 2021, 3-8. doi: 10.21608/mjvh.2021.158270
Mousa, N., Abdel-Razik, A., Mousa, E., Elbadrawy, T., Hosni, K., Mousa, A., Taha, A., Elmetwalli, A. (2021). 'Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review', EKB Journal Management System, 5.2(2), pp. 3-8. doi: 10.21608/mjvh.2021.158270
Mousa, N., Abdel-Razik, A., Mousa, E., Elbadrawy, T., Hosni, K., Mousa, A., Taha, A., Elmetwalli, A. Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review. EKB Journal Management System, 2021; 5.2(2): 3-8. doi: 10.21608/mjvh.2021.158270

Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review

Medical Journal of Viral Hepatitis
Article 2, Volume 5.2, Issue 2, March 2021, Page 3-8  XML PDF (206.13 K)
Document Type: Review articles
DOI: 10.21608/mjvh.2021.158270
View on SCiNiTO View on SCiNiTO
Authors
Nasser Mousa1; Ahmed Abdel-Razik1; Eman Mousa* 2; Tasnim Elbadrawy3; Khaled Hosni3; Aya Mousa4; Ahmed Taha3; Alaa Elmetwalliorcid 5
1Tropical Medicine Department, Mansoura University, Mansoura, Egypt
2Faculty of Dentistry, Mansoura University, Mansoura, Egypt
3Faculty of Medicine, October 6 University, Egypt
4Faculty of physical therapy, Galala university, Egypt
5Department of Clinical Trial Research Unit, Egyptian Liver Research Institute and Hospital, Mansoura, Egypt.
Abstract
Background: Nowadays, the new coronavirus-induced severe acute respiratory syndrome (COVID-19) outbreak was primarily stated in December 2019. Three months later, the Director-General of the World Health Organization, avowed the COVID-19 a global pandemic. Gathered evidence discloses that coagulation syndrome is repeatedly seen in COVID-19, and the incidence is higher in severe cases. The worsening lung functions and coagulopathy are some of the most significant poor prognostic criteria in the outcome of COVID-19. The pragmatic coagulopathy in patients hospitalized with COVID-19 (COVID-19 associated coagulopathy) is categorized by the increased level of D-dimer and fibrinogen/fibrin degradation products. They are interrelated with the severity of COVID-19. This elevation will aid the arrangement of the patients consistent with the disease severity and management. These coagulation parameters elevation can point to a poor prognosis. Coagulopathy in COVID-19 mainly affects immobilized patients, those in critical care units, and those who have extra risk factors that predispose to coagulopathy, for instance, acute inflammatory conditions and hypoxia. The exact pathogenesis of hypercoagulability in COVID-19 is unwell understood. The signs suggest that the COVID‐19 coagulopathy is an evolving phenomenon in which endothelial damage, platelet aggregation, augmented innate immune response, and other measures as systemic inflammation favoring coagulation would divide up the severity of this disease. Understanding the pathophysiology of COVID-19 related coagulopathy is crucial for suitable treatment and monitoring of these patients. Encouraging interest in the potential uses of anticoagulation in COVID-19 particularly is the use of heparin that has a potential benefit over other anticoagulants due to its anticoagulant role, anti-inflammatory, and potentially anti-viral properties.
Keywords
COVID-19; coagulopathy; endothelial dysfunction; D-dimer
Statistics
Article View: 382
PDF Download: 645